CAR-T cell therapy
A patient's own immune cells are engineered to find and kill their cancer.
Health and medicine · Biotechnology · No. 433
- Networked and AI age
- Readiness 9 of 9
- Process
A living drug: a patient's own immune cells are reprogrammed to hunt their cancer, then multiplied and returned in one infusion.
Chart: Illustration: CAR-T cell therapy
Where it comes from
Chart: Map of where it comes from
Immunologists in 1989 gave T cells receptors with antibody-type targeting. At Penn the approach was first tested in patients with chronic lymphocytic leukaemia in 2010, and Kymriah was approved in 2017.
Three things to know
- The idea of joining an antibody's targeting part to a T-cell receptor was first reported in 1989.
- Kymriah, approved in August 2017, was the first therapy based on gene transfer approved by the US regulator.
- Seven CAR-T therapies were approved in the United States by 2025, all for blood cancers such as leukaemia, lymphoma and myeloma.
The journey
- 1 CollectionBlood is drawn and the T cells are separated out
- 2 EngineeringIn a manufacturer's laboratory the cells are given a gene for a chimeric antigen receptor
- 3 GrowthThe changed cells are multiplied to hundreds of millions
- 4 InfusionThey go back into the patient in a single infusion
- 5 AttackThe cells find cancer cells carrying the target marker and kill them